Breast Cancer Research Centre - WA | Nedlands, Australia
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC).
The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. Assessment of a variety of correlative analysis, including evaluation of the effect of palbociclib in genomically defined tumor subgroups, is planned.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
FFPE tumor tissue block must be confirmed to be received at the central sample repository prior to randomization.
-Patients must either be initiating or have already started adjuvant hormonal treatment. -
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
5,796 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal